RAASI, NSAIDs, antidiabetics, and anticoagulants: More data needed to be labeled as harmful or neutral in SARS-CoV-2 infection.

Gremese, Elisa; Alivernini, Stefano; Ferraccioli, Gianfranco

Gremese, Elisa; Alivernini, Stefano; Ferraccioli, Gianfranco.

Gremese E; Rheumatology, Department of Medicine, Università Cattolica Sacro Cuore, 00168 Rome, Italy.
Alivernini S; Fondazione Policlinico Gemelli-Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica Sacro Cuore, 00168 Rome, Italy.
Ferraccioli G; Fondazione Policlinico Gemelli-Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica Sacro Cuore, 00168 Rome, Italy.

Proc Natl Acad Sci U S A ; 118(20)2021 05 18.

Article in English | MEDLINE | ID: covidwho-1225543

Subject(s)

COVID-19 Drug Treatment; Angiotensin-Converting Enzyme Inhibitors/therapeutic use; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use; Anticoagulants/therapeutic use; COVID-19/epidemiology; COVID-19/pathology; Humans; Hypoglycemic Agents/therapeutic use; Renin-Angiotensin System/drug effects; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Observational study Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Pnas.2025609118

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google